×
About 1,741 results

ALLMedicine™ Malignant Hyperthermia Center

Research & Reviews  843 results

Successful management of hypothermic cardiopulmonary bypass in a malignant hyperthermia...
https://doi.org/10.4103/aca.ACA_245_18
Annals of Cardiac Anaesthesia; Agarwal S, Graham K et. al.

Jul 20th, 2020 - Malignant hyperthermia (MH) is a potentially lethal reaction in those that are genetically predisposed, frequently triggered by inhaled anesthetics. MH is often difficult to diagnose because it is accompanied by signs and symptoms that are shared ...

Transient Receptor Potential Cation Channels and Calcium Dyshomeostasis in a Mouse Mode...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367496
Anesthesiology Rafael Lopez J, Kaura V et. al.

Jul 15th, 2020 - Until recently, the mechanism for the malignant hyperthermia crisis has been attributed solely to sustained massive Ca release from the sarcoplasmic reticulum on exposure to triggering agents. This study tested the hypothesis that transient recept...

Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence v...
https://doi.org/10.1007/s40279-020-01318-4
Sports Medicine (Auckland, N.Z.); Laitano O, Murray KO et. al.

Jul 5th, 2020 - Exertional heat stroke (EHS) and malignant hyperthermia (MH) are life-threatening conditions, triggered by different environmental stimuli that share several clinical symptoms and pathophysiological features. EHS manifests during physical activity...

Availability of dantrolene for the management of malignant hyperthermia crises: Europea...
https://doi.org/10.1016/j.bja.2020.04.089
British Journal of Anaesthesia; Glahn KPE, Bendixen D et. al.

Jun 27th, 2020 - Faced with a malignant hyperthermia crisis, the immediate access to sufficient dantrolene is essential to achieve the best possible outcome for the patient. However, malignant hyperthermia crises are rare, and there may be administrative pressures...

Functional analysis of newly identified RYR1 variants in patients susceptible to malign...
https://doi.org/10.1007/s00540-020-02803-w
Journal of Anesthesia; Noda Y, Yasuda T et. al.

Jun 14th, 2020 - This study aimed to evaluate whether the three ryanodine receptor type 1 (RYR1) variants (p.Ser2345Thr, p.Ser2345Arg, and p.Lys3367Arg) which we identified in Japanese malignant hyperthermia (MH) patients with a clinical grading scale rank of 6 we...

see more →

Guidelines  5 results

Malignant Hyperthermia-Susceptible Adult Patient and Ambulatory Surgery Center: Society...
https://doi.org/10.1213/ANE.0000000000004257
Anesthesia and Analgesia; Urman RD, Rajan N et. al.

Jun 5th, 2019 - This document represents a joint effort of the Society for Ambulatory Anesthesia (SAMBA) and the Ambulatory Surgical Care Committee of the American Society of Anesthesiologists (ASA) concerning the safe anesthetic care of adult malignant hyperther...

JSA guideline for the management of malignant hyperthermia crisis 2016.
https://doi.org/10.1007/s00540-016-2305-z
Journal of Anesthesia;

Mar 1st, 2017 - Malignant hyperthermia (MH) can be fatal if the crisis is not appropriately treated. It is an inherited disease usually triggered by the administration of volatile inhalational anesthetics and/or succinylcholine, a muscle relaxant. In a patient wi...

European Malignant Hyperthermia Group guidelines for investigation of malignant hyperth...
https://doi.org/10.1093/bja/aev225
British Journal of Anaesthesia; Hopkins PM, Rüffert H et. al.

Jul 18th, 2015 - It is 30 yr since the British Journal of Anaesthesia published the first consensus protocol for the laboratory diagnosis of malignant hyperthermia susceptibility from the European Malignant Hyperthermia Group. This has subsequently been used in mo...

Special article: Creation of a guide for the transfer of care of the malignant hyperthe...
https://doi.org/10.1213/ANE.0b013e3182373b4a
Anesthesia and Analgesia; Larach MG, Dirksen SJ et. al.

Nov 4th, 2011 - Volatile anesthetics and/or succinylcholine may trigger a potentially lethal malignant hyperthermia (MH) event requiring critical care crisis management. If the MH triggering anesthetic is given in an ambulatory surgical center (ASC), then the pat...

Recognizing and managing a malignant hyperthermia crisis: guidelines from the European ...
https://doi.org/10.1093/bja/aeq243
British Journal of Anaesthesia; Glahn KP, Ellis FR et. al.

Sep 14th, 2010 - Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is likely to make it even rarer, leading to the potential risk o...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  873 results

Successful management of hypothermic cardiopulmonary bypass in a malignant hyperthermia...
https://doi.org/10.4103/aca.ACA_245_18
Annals of Cardiac Anaesthesia; Agarwal S, Graham K et. al.

Jul 20th, 2020 - Malignant hyperthermia (MH) is a potentially lethal reaction in those that are genetically predisposed, frequently triggered by inhaled anesthetics. MH is often difficult to diagnose because it is accompanied by signs and symptoms that are shared ...

Transient Receptor Potential Cation Channels and Calcium Dyshomeostasis in a Mouse Mode...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367496
Anesthesiology Rafael Lopez J, Kaura V et. al.

Jul 15th, 2020 - Until recently, the mechanism for the malignant hyperthermia crisis has been attributed solely to sustained massive Ca release from the sarcoplasmic reticulum on exposure to triggering agents. This study tested the hypothesis that transient recept...

Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence v...
https://doi.org/10.1007/s40279-020-01318-4
Sports Medicine (Auckland, N.Z.); Laitano O, Murray KO et. al.

Jul 5th, 2020 - Exertional heat stroke (EHS) and malignant hyperthermia (MH) are life-threatening conditions, triggered by different environmental stimuli that share several clinical symptoms and pathophysiological features. EHS manifests during physical activity...

Availability of dantrolene for the management of malignant hyperthermia crises: Europea...
https://doi.org/10.1016/j.bja.2020.04.089
British Journal of Anaesthesia; Glahn KPE, Bendixen D et. al.

Jun 27th, 2020 - Faced with a malignant hyperthermia crisis, the immediate access to sufficient dantrolene is essential to achieve the best possible outcome for the patient. However, malignant hyperthermia crises are rare, and there may be administrative pressures...

Functional analysis of newly identified RYR1 variants in patients susceptible to malign...
https://doi.org/10.1007/s00540-020-02803-w
Journal of Anesthesia; Noda Y, Yasuda T et. al.

Jun 14th, 2020 - This study aimed to evaluate whether the three ryanodine receptor type 1 (RYR1) variants (p.Ser2345Thr, p.Ser2345Arg, and p.Lys3367Arg) which we identified in Japanese malignant hyperthermia (MH) patients with a clinical grading scale rank of 6 we...

see more →

News  9 results

FDA rejects Eagle Pharmaceuticals' heat stroke treatment
https://www.reuters.com/article/us-eagle-pharms-fda/fda-rejects-eagle-pharmaceuticals-heat-stroke-treatment-idUSKBN1AB2D8

Jul 26th, 2017 - (Reuters) - Eagle Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration declined to approve its drug Ryanodex to treat heat stroke and requested an additional clinical trial, sending its shares down 20 percent. The drug, whic...

Coronavirus (COVID-19) Update: Daily Roundup May 19, 2020
http://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-19-2020

For Immediate Release: May 19, 2020 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: Today, the FDA approved succinylcholine chloride injection USP 200 mg/10...

Coronavirus (COVID-19) Update: Daily Roundup June 17, 2020
http://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-17-2020

For Immediate Release: June 17, 2020 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On June 16, 2020, the FDA approved an abbreviated new drug application ...

Study explains link between malignant hyperthermia and bleeding abnormalities
https://www.mdedge.com/hematology-oncology/article/187232/thrombosis/study-explains-link-between-malignant-hyperthermia-and-bleeding
HT Staff

Jul 6th, 2016 - Lab mouse A new study helps explain why some patients with malignant hyperthermia may suffer from excessive bleeding. The findings suggest a mutation that causes malignant hyperthermia can disrupt calcium signaling in vascular smooth muscle cells,.

Surgicenters Need Plans for Malignant Hyperthermia
https://www.medpagetoday.com/surgery/anesthesiology/30430

Dec 29th, 2011 - Action Points Explain that ambulatory surgical centers need to have policies and equipment in place to handle malignant hyperthermia, a rare but potentially lethal complication of anesthesia. Point out that facilities must have the muscle relaxant...

see more →

Patient Education  4 results see all →